Dupilumab-pediatric skin barrier function and lipidomics study in patients with Atopic Dermatitis in China

Trial Identifier:	LPS17244
Sponsor:	Sanofi
Start Date:	February 2023
Primary Completion Date:	December 2023
Study Completion Date:	March 2024
Condition:	Eczema

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Beijing, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.